The use of doxorubicin followed by zoledronic acid reduced tumor size substantially in a mouse model of breast cancer that does not have bone metastases.
The use of doxorubicin followed by zoledronic acid reduced tumor size substantially in a mouse model of breast cancer that does not have bone metastases.